Impact of COVID-19 on HV trials [Study Per­for­mance]

posted by drgunasakaran1  – 2021-06-03 08:06 (1138 d 22:39 ago) – Posting: # 22389
Views: 1,995

Dear Ms Silvia Giarcovich,

❝ (always with a nurse at all times and a medical doctor visiting all the volunteers, etc etc)?


It is highly advisable to keep the volunteers under the medical supervision of physicians for a specified period after administration of investigational product. Also, in case of any emergency, housing the subjects in their home is not practically safe to manage any serious adverse events.

❝ One possibility would be to include a PCR / COVID-19 test both at screening and before each administration period and at the end of the study.


Yes. We can include negative RT-PCR as one of the subject's inclusion criteria during screening/each check-in/post study evaluation in the protocol itself to minimize the risk of infection/transmission of Coronavirus during the housing period.

Dr S Gunasakaran MBBS MD
Disclaimer: The replies/posts are my personal opinions and it does not represent my company views on the same.

Complete thread:

UA Flag
Activity
 Admin contact
23,101 posts in 4,857 threads, 1,644 registered users;
81 visitors (0 registered, 81 guests [including 5 identified bots]).
Forum time: 06:45 CEST (Europe/Vienna)

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5